Valuation Watch: As Biopharma IPOs Return, Does Value?
This article was originally published in Start Up
Executive Summary
At least a dozen companies that roughly fit the description of a venture-backed, R&D focused biotech or small pharmaceutical company have gone public since mid-2009. Here we look at how valuations stack up compared to M&A and previous IPO windows.
You may also be interested in...
Zogenix Faces A Tough Biotech IPO Climate
The San Diego biotech significantly lowered its IPO price to $4 per share as it entered an unwelcoming market.
Zogenix Faces A Tough Biotech IPO Climate
The San Diego biotech significantly lowered its IPO price to $4 per share as it entered an unwelcoming market.
Start-Up Quarterly Statistics, Q3 2010
Biopharma, medical device, and in vitro diagnostics start-ups brought in a total of $780 million in Q3 2010, a 29% jump from the previous quarter and a 50% increase from Q3 2009. A total of eight start-up acquisitions closed in Q3, quite a jump from the first two quarters of 2010. The third quarter saw 14 biopharma alliances covering a wide range of therapeutic categories, the most popular indication being cancer.